

Instance: composition-en-d843c48300874227785506f7092e03c1
InstanceOf: CompositionUvEpi
Title: "Composition for fulvestrant Package Leaflet"
Description:  "Composition for fulvestrant Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - fulvestrant"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  What is in this leaflet 
1. What Fulvestrant Mylan is and what it is used for  
2. What you need to know before you use Fulvestrant Mylan  
3. How to use Fulvestrant Mylan  
4. Possible side effects  
5. How to store Fulvestrant Mylan  
6. Contents of the pack and other information 
         </div>"""   
          

* section[=].section[+]
  * title =  "1. What fulvestrant is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What fulvestrant is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Fulvestrant Mylan contains the active substance fulvestrant, which belongs to the group of estrogen 
blockers. Estrogens, a type of female sex hormones, can in some cases be involved in the growth 
of breast cancer.  </p>
<p>Fulvestrant Mylan is used either:<br />
* alone, to treat postmenopausal women with a type of breast cancer called estrogen receptor 
positive breast cancer that is locally advanced or has spread to other parts of the body 
(metastatic), or 
* in combination with palbociclib to treat women with a type of breast cancer called hormone 
receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, that is 
locally advanced or has spread to other parts of the body (metastatic). Women who have not 
reached menopause will also be treated with a medicine called a luteinizing hormone 
releasing hormone (LHRH) agonist. </p>
<p>When fulvestrant is given in combination with palbociclib, it is important that you also read the 
package leaflet for palbociclib. If you have any questions about palbociclib, please ask your doctor. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take fulvestrant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take fulvestrant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Fulvestrant Mylan 
- if you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in 
section 6) 
- if you are pregnant or breast-feeding 
- if you have severe liver problems </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist or nurse before using Fulvestrant Mylan if any of these apply to 
you:</p>
<ul>
<li>kidney or liver problems </li>
<li>low numbers of platelets (which help blood clotting) or bleeding disorders  </li>
<li>previous problems with blood clots </li>
<li>osteoporosis (loss of bone density) </li>
<li>alcoholism </li>
</ul>
<p>Children and adolescents 
Fulvestrant Mylan is not indicated in children and adolescents under 18 years. </p>
<p>Other medicines and Fulvestrant Mylan </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. 
In particular, you should tell your doctor if you are using anticoagulants (medicines to prevent 
blood clots). </p>
<p>Pregnancy and breast-feeding 
You must not use Fulvestrant Mylan if you are pregnant. If you can become pregnant, you should 
use effective contraception while you are being treated with Fulvestrant Mylan and for 2 years after 
your last dose. </p>
<p>You must not breast-feed while on treatment with Fulvestrant Mylan.  </p>
<p>Driving and using machines 
Fulvestrant Mylan is not expected to affect your ability to drive or use machines. However, if you 
feel tired after treatment do not drive or use machines. </p>
<p>Fulvestrant Mylan contains 10% w/v alcohol (ethanol) i.e. 500 mg in each 5 ml, equivalent 
to less than 25 ml beer or 10 ml wine per one treatment dose (i.e. two syringes). The small 
amount of alcohol in this medicine will not have any noticeable effects. </p>
<p>Fulvestrant Mylan contains benzyl alcohol 
This medicine contains 500 mg benzyl alcohol in each 5 ml which is equivalent to 100 mg/ml (10% 
w/v). Benzyl alcohol may cause allergic reactions.  </p>
<p>Fulvestrant Mylan contains benzyl benzoate 
This medicine contains 750 mg benzyl benzoate in each 5 ml, which is equivalent to 150 mg/ml 
(15%w/v). </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take fulvestrant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take fulvestrant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you.  Check with your 
doctor or pharmacist if you are not sure.   </p>
<p>The recommended dose is 500 mg fulvestrant (two 250 mg/5 ml injections) given once a month, 
with an additional 500 mg dose given 2 weeks after the initial dose. </p>
<p>Your doctor or nurse will give you Fulvestrant Mylan as a slow intramuscular injection, one into 
each of your buttocks. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or 
nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>You may need immediate medical treatment if you experience any of the following side 
effects:  </p>
<ul>
<li>Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or 
throat that may be signs of anaphylactic reactions </li>
<li>Thromboembolism (increased risk of blood clots)* </li>
<li>
<p>Inflammation of the liver (hepatitis)  </p>
</li>
<li>
<p>Liver failure </p>
</li>
</ul>
<p>Tell your doctor, pharmacist, or nurse if you notice any of the following side effects: </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Injection site reactions, such as pain and/or inflammation<br />
<em> Abnormal levels of liver enzymes (in blood tests)</em> 
* Nausea (feeling sick)<br />
<em> Weakness, tiredness</em> 
* Joint and musculoskeletal pain 
* Hot flushes 
* Skin rash 
* Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or 
throat </p>
<p>All other side effects: </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Headache 
* Vomiting, diarrhoea, or loss of appetite<em> 
* Urinary tract infections 
* Back pain</em> 
* Increase of bilirubin (bile pigment produced by the liver)<br />
<em> Thromboembolism (increased risk of blood clots)</em> 
* Decreased levels of platelets (thrombocytopenia) 
* Vaginal bleeding 
* Lower back pain irradiating to leg on one side (sciatica) 
* Sudden weakness, numbness, tingling, or loss of movement in your leg, especially on only 
one 
side of your body, sudden problems with walking or balance (peripheral neuropathy) </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Thick, whitish vaginal discharge and candidiasis (infection) 
* Bruising and bleeding at the site of injection 
* Increase of gamma-GT, a liver enzyme seen in a blood test 
* Inflammation of the liver (hepatitis) 
* Liver failure 
* Numbness, tingling and pain 
* Anaphylactic reactions </p>
<ul>
<li>Includes side effects for which the exact role of Fulvestrant Mylan cannot be assessed due to the 
underlying disease. </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store fulvestrant"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store fulvestrant"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton or syringe labels after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Store and transport refrigerated (2 C - 8 C).  </p>
<p>Temperature excursions outside 2 C - 8 C should be limited and not exceeding a 28 day period 
where the average storage temperature for the product is below 25 C (but above 2 C - 8 C). 
After temperature excursions, the product should be returned immediately to the recommended 
storage conditions (store and transport in a refrigerator 2 C - 8 C). Temperature excursions have 
a cumulative effect on the product quality and the 28 day time period must not be exceeded over 
the duration of the shelf life of Fulvestrant Mylan. Exposure to temperatures below 2 C will not 
damage the product providing it is not stored below   20 C.  </p>
<p>Keep the pre-filled syringe in the original package in order to protect from light. </p>
<p>Your healthcare professional will be responsible for the correct storage, use and disposal of 
Fulvestrant Mylan. </p>
<p>This medicine may pose a risk to the aquatic environment. Do not throw away any medicines via 
wastewater or household waste.  Ask your pharmacist how to throw away medicines you no 
longer use.  These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Fulvestrant Mylan contains<br />
- The active substance is fulvestrant. Each pre-filled syringe (5 ml) contains 250 mg 
fulvestrant. 
- The other ingredients (excipients) are benzyl benzoate (see section 2  Fulvestrant Mylan 
contains benzyl benzoate ), benzyl alcohol (see section 2  Fulvestrant Mylan contains benzyl 
alcohol ), ethanol anhydrous (see section 2  Fulvestrant Mylan contains 10% w/v alcohol 
(ethanol) ), castor oil, refined. </p>
<p>What Fulvestrant Mylan looks like and contents of the pack 
Fulvestrant Mylan is a clear, colourless to yellow, viscous solution in a pre-filled syringe fitted with 
a tamper-evident closure, containing 5 ml solution for injection.<br />
Fulvestrant Mylan has 4 pack presentations, either a pack containing 1 glass pre-filled syringe or a 
pack containing 2 glass pre-filled syringes or a pack containing 4 glass pre-filled syringes or a 
pack containing 6 glass pre-filled syringes. Safety needles (BD SafetyGlide) for connection to each 
barrel are also provided.  </p>
<p>Not all pack sizes may be marketed.  </p>
<p>Marketing Authorisation Holder<br />
MYLAN PHARMACEUTICALS LIMITED 
Damastown Industrial Park 
Mulhuddart<br />
Dublin DUBLIN 
Ireland </p>
<p>Manufacturer 
MYLAN TEORANTA 
Inverin 
Co. Galway 
IRELAND </p>
<p>MYLAN GERMANY GmbH 
Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1 
Bad Homburg v. d. Hoehe 
Hessen, 61GERMANY </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Mylan bvba/sprl 
Tel/T l: + 32 (0)2 658 61<br />
Lietuva 
Mylan Healthcare UAB<br />
Tel: +370 5 205 1  </p>
<p>: +359 2 44 55<br />
Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ s.r.o. 
Tel: +420 222 004<br />
Magyarorsz g 
Mylan EPD Kft. 
Tel.: + 36 1 465 2 
Danmark 
Viatris ApS 
Tlf: +45 28 11 69 32  </p>
<p>Malta 
V.J.Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH<br />
Tel: + 49 800 0700<br />
Nederland 
Mylan BV 
Tel: +31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti filiaal<br />
Tel: + 372 6363 Norge 
Viatris AS 
Tlf: + 47 66 75 33  </p>
<p>Generics Pharma Hellas  <br />
 :  +30 210 993 6410  </p>
<p>sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 
Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102<br />
Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64  </p>
<p>France 
Viatris Sant<br />
T l: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 21 412 72<br />
Hrvatska 
Mylan Hrvatska d.o.o. 
Tel: +385 1 23 50<br />
Rom nia 
BGP Products SRL 
Tel: + 40 372 579<br />
Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711 
Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
 sland 
Icepharma hf. 
S mi: + 354 540 8 
Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: + 358 20 720 9 </p>
<p>Varnavas Hadjipanayis Ltd 
 : + 357 2220 7 
Sverige 
Viatris AB<br />
Tel: + 46 (0)8 630 19<br />
Latvija 
Mylan Healthcare SIA<br />
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel:  +353 18711 
This leaflet was last revised in {MM/YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

